Radiotherapy as the primary and palliative treatment for patients aged 75 and over with locally advanced and metastatic non-small cell lung cancer: Analysis of 45 cases with a review of the literature

Basit Öğe Kaydı
dc.authorscopusid8832725600
dc.authorscopusid6506348846
dc.authorscopusid16246543600
dc.authorscopusid24177226800
dc.authorscopusid7003303984
dc.authorscopusid6603174493
dc.authorscopusid6602475427
dc.contributor.authorAksu G.
dc.contributor.authorFayda M.
dc.contributor.authorSaynak M.
dc.contributor.authorSaglamer E.K.
dc.contributor.authorOral E.N.
dc.contributor.authorKizir A.
dc.contributor.authorKaradeniz A.
dc.date.accessioned2024-06-12T10:28:23Z
dc.date.available2024-06-12T10:28:23Z
dc.date.issued2008
dc.description.abstractAim: To evaluate the prognostic factors and treatment results of Turkish patients aged 75 and over with locally advanced and metastatic non-small cell lung cancer (NSCLC). Patients and Methods: Forty-five patients ? 75 years were evaluated. The median age was 78 (75-93). Thirty-four patients (75%) had stage IIIB and 11 patients had stage IV disease (25%). Fourteen patients (41%) with stage IIIB disease were treated with curative radiotherapy (RT), 18 patients (52%) with palliative RT and 2 patients (5%) were treated with only chemotherapy (CT). Results: The one-year survival rate was 37%. The overall median survival was 12.7 months in stage IIIB and 7.67 months in stage IV. In univariate analysis, advanced stage (p=0.0006), performance status (p=0.056), absence of radiotherapy (p=0.0008) and weight loss (p=0.0053) adversely affected survival. In multivariate analysis only stage IV was found to be a statistically significant independent poor prognostic factor (p=0.0025 HR=0.2760 (0.12-0.60) 95% confidence interval). Conclusion: In Turkish patients, with NSCLC, aged 75 or over, stage IV disease was associated with poor prognosis. The higher radiotherapy doses did not improve survival in patients with stage IIIB disease and the prognosis with only radiotherapy is similar to the results of chemoradiation in the literature in this age group.en_US
dc.identifier.endpage20en_US
dc.identifier.issn1019-1941
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-43449096059en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage11en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17229
dc.identifier.volume21en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofMarmara Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapy; Elderly; Lung Cancer; Prognostic Factors; Radiotherapyen_US
dc.subjectCisplatin; Advanced Cancer; Aged; Article; Cancer Localization; Cancer Staging; Cancer Survival; Clinical Article; Disease Association; Disease Course; Dysphagia; Febrile Neutropenia; Female; Human; Lung Non Small Cell Cancer; Male; Metastasis; Neutropenia; Pneumonia; Prognosis; Survival Rateen_US
dc.titleRadiotherapy as the primary and palliative treatment for patients aged 75 and over with locally advanced and metastatic non-small cell lung cancer: Analysis of 45 cases with a review of the literatureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu